马拉维隐球菌脑膜炎诊断与治疗可及性改善的临床影响与成本效果
该研究使用CEPAC-I模型模拟马拉维启动HIV care且血清CrAg阳性的PWH,比较现行 care 与7种扩展诊断/治疗策略。结果显示提高LAmB/5FC/Fluc可及性至98%可改善生存且具成本效果,联合CrAgSQ加确认性LP策略ICER为US$380/QALY。
要点
- 提高LAmB/5FC/Fluc可及性至98%可增加1年生存率2.2%且具成本效果。
- CrAgSQ加确认性LP联合治疗扩展策略增加1年生存率6.0%,ICER为US$380/QALY。
- 结果对检测特征和 uptake 敏感,需结合当地实际调整。
核心结论
- 在马拉维及类似 settings,改善LAmB/5FC/Fluc可及性并扩展诊断以发现无症状CM可改善临床结局且具成本效果。
研究设计与样本
- 使用CEPAC-I模型模拟马拉维启动HIV care且血清CrAg阳性的PWH,比较现行 care 与7种干预策略。
- 模拟队列平均CD4 27/µL、年龄37岁,16%有症状CM、28%无症状CM、56%无症状隐球菌血症。
主要发现
- 现行 care 的1年生存率为70%,10.67 QALYs,成本US$2290/人。
- LAmB/5FC/Fluc可及性98%策略增加生存率2.2%、QALYs增加0.33(未折扣),终生成本US$2320/人,ICER为US$140/QALY。
- CrAgSQ加确认性LP联合LAmB/5FC/Fluc可及性98%策略增加1年生存率6.0%、QALYs增加0.97、成本增加US$190/人,ICER为US$380/QALY。
- 结果对检测特征和 uptake 敏感。
关键数值与推荐
- 成本效果阈值评估为US$150/QALY和US$600/QALY。
- LAmB/5FC/Fluc策略ICER为US$140/QALY,联合诊断策略ICER为US$380/QALY。
临床怎么用
- 在马拉维及类似 settings,可优先考虑提高LAmB/5FC/Fluc可及性并扩展CrAgSQ加确认性LP诊断路径以改善CM相关结局。
局限性
- 结果为模型模拟,对检测特征和 uptake 敏感,需本地数据验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cryptococcal meningitis (CM) causes 13%-20% of deaths among people with HIV (PWH) globally. We examined the cost-effectiveness of improving access to CM diagnostics and treatment among PWH initiating HIV care with a positive serum cryptococcal antigen (CrAg) test in Malawi. METHODS: We used the CEPAC-I model to simulate (1) Current care (CM treatment if diagnosed with CM; otherwise preemptive fluconazole) and assessed 7 intervention strategies to expand care: (2) lumbar puncture (LP); (3) semi-quantitative serum CrAg (CrAgSQ) alone; or (4) CrAgSQ plus confirmatory LP for asymptomatic people with CrAg+; and (5) 98% access to liposomal amphotericin B/flucytosine/fluconazole (LAmB/5FC/Fluc) for diagnosed CM, as well as improving access to CM treatment with each diagnostic strategy (6, 7, 8). The simulated cohort has mean CD4 27/µL, age 37 years; 16% have symptomatic CM, 28% asymptomatic CM, and 56% asymptomatic cryptococcemia. Model outcomes include 1-year survival, quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs) assessed at 2 cost-effectiveness thresholds: US$150/QALY and US$600/QALY. RESULTS: Current care results in 70% 1-year survival, 10.67 QALYs, and costs US$2290/person. 98% access to LAmB/5FC/Fluc increases survival (+2.2%) and QALYs (+0.33 undiscounted QALYs) at lifetime costs of US$2320/person (ICER, US$140/QALY). CrAgSQ plus confirmatory LP for asymptomatic CrAg+ and 98% access to LAmB/5FC/Fluc results in +6.0% 1-year survival, +0.97 QALYs, +US$190/person (ICER, US$380/QALY). Results are sensitive to test characteristics and uptake. INTERPRETATION: Improving access to LAmB/5FC/Fluc and expanding diagnostics to improve detection of asymptomatic CM would improve clinical outcomes and be cost-effective in Malawi and similar settings.
引用
- Feser M, Maphosa T, Shroufi A, et al. Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi. Clin Infect Dis. 2026. PMID: 42206850. doi:10.1093/cid/ciag270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。